Life Sciences

Marlborough pharmaceutical manufacturer Sunovion is seeking federal approval for a drug to treat motor fluctuations in Parkinson's disease patients.

Holliston biotech Biostage ended 2017 with about $4 million in cash on hand, and that will carry the company only partially through this year's third quarter.

Holliston medical device maker Biostage has added another children's hospital executive as the company continues to remake itself into a child-focused biotech company.

Funding for Biostage's bioengineered throat organ implants continues to pile up, as the Holliston company announced Thursday it has been awarded a grant worth up to $1.7 million.

Marlborough-based biotech RXi Pharmaceuticals ended 2017 with $3.6 million in cash, about a third of what if had at the end of 2016, according to a financial statement released by the company Monday.

A Cambridge-based life sciences facility developer is proposing to renovate and expand the former MetroWest Daily News site in Framingham for several unannounced tenants.

Holliston biotech Biostage is eyeing formal clinical trials after results of a large animal study show the company's artificial throat implants can regenerate a functioning esophagus.

Newburyport pharmaceutical manufacturer PCI Synthesis announced last week that it has achieved double-digit growth for the fourth consecutive year, along with hitting new milestones and entering into new markets in the start of 2018, which marks the company's 20th anniversary.

Marlborough medical device maker Boston Scientific has acquired a privately-held British firm that has developed a device to help treat pancreatic cancer.

Holliston life sciences firm Harvard Biosciences reported a $900,000 loss in 2017, as revenues declined by $2.6 million for the year.